Mind Medicine (MindMed) Inc

NASDAQ:MNMDUnited States

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

Contact Information

Headquarters

One World Trade Center, Suite 8500NEW YORK, NY, United States 10007

Phone

212-220-6633

Fax

888-848-3972

Executives

Independent Chairman of the Board

Carol Vallone

Executive President

Miriam Wernli

Chief Development Officer

Robert Barrow

Independent Vice Chairman of the Board

Andreas Krebs

Chief Accounting Officer

Carrie Liao